



# CanaQuest Medical Corp - A Clinical-Stage Life Sciences Company Secures Success

**The drugs industry is constantly evolving, driven forward by numerous innovations and discoveries. We look at one of these industry leaders, CanaQuest Medical, to discover how they've achieved success in 2022's Global Excellence Awards from GHP. The firm was named Best Medical Cannabis and Botanical Oils Product Development Company, 2022 - North America, so we take a closer look to discover why.**

The power of medical treatments is formidable but must consistently expand to meet the needs of the moment. When looking at CanaQuest, we see a team who have made it their mission to advance the state of botanical-based medicine. In the constantly evolving drugs industry, their dream has been to deploy best-practice science and medicine, clinical research, and emerging technologies in order to uncover the secrets held by the incredible miracle of nature.

Since opening their doors, the CanaQuest team have focused in on the various neurological conditions that many struggle with on a daily basis. Conditions such as anxiety, depression, schizophrenia, and Post Traumatic Stress Disorder "PTSD", including addiction all have the potential to be managed and reduced through appropriate therapeutics. The team at CanaQuest stand apart not because of their focus on these impactful conditions, but on the way in which it has prioritised the drug discovery and development of next generation targeted therapeutics within the endocannabinoid system and specific brain receptors.

The team's game changing approach has allowed them

to develop incredible CBD and THC based formations. These drug candidates are positioned to enter pre-approved and pending clinical trials. Rx CQ-001, supported by CBD molecules + formula, is designed to synergistically attach to the PPAR receptor allowing Rx CQ-001 to cross the blood-brain barrier (BBB) to target the central nervous system (the brain) for amplified effects and efficacy. The Company has identified the regulatory pathways to obtain Rx Drug Identification Numbers (DINs) in Canada and the USA for Epilepsy rare neurological conditions, projected 3 years.

Rx CQ-002, supported by THC molecules + formula, is a safer alternative to all other THC products with pre-clinical trials demonstrating a reversal of depression-like and schizophrenia related symptoms. The success of both drugs candidates has seen the company publish the pre-clinical trial results in the peer-reviewed European Journal of Neuroscience to demonstrate their effectiveness. This high quality of research is shown through the way in which the team collaborates with various universities. At Western University, a team led by Dr. Steven Laviolette, a neuroscientist, with decades of



research experience, focused on novel cannabinoid and botanical pharmacotherapies, has successfully completed the pre-clinical trials. Their tireless efforts have been key to securing such impressive results during the development of both formulations. Additionally, renowned institutions such as the University of Montreal, McMaster University, and Ontario Brain are major partners for pre-approved and pending clinical trials.

To enhance their offerings, the team have explored the potential of artificial intelligence in order to diagnose and evaluate mental health at the beginning and through the medication period. The use of machine learning has not just advanced the work that the team at CanaQuest has done. It has driven the growth of the mental health industry as a whole. This sector has had a

major impact on how we live, with spending on treatments rising in every country in the world. This is shown by the fact that nearly 1 in 5 North Americans has some type of mental health condition.

Looking ahead, having strong drug candidates and access to two commercial-ready Master Formulations for treating mental health ailments means having incredible potential for growth. The CanaQuest team's work is truly world-leading, which is why they have managed to achieve such remarkable success. As the demand for their incredible formulations continues to grow, it's clear that this is a path with an enormous amount of research and commercial potential to exploit.

Company: CanaQuest Medical Corp  
Name: Paul Ramsay, President  
Email: paul@canaquest.com